Phase Ia/b Dose-Escalation Study Followed by Expansion Cohorts of NGM120, a GFRAL Antagonist Monoclonal Antibody Blocking GDF15 Signaling, in Patients With Advanced Solid Tumors and Pancreatic Cancer Using Combination Therapy
Summary
The purpose of this phase Ia/b study is to evaluate the safety of NGM120 in patients with advanced solid tumors, including pancreatic cancer.
General Information
NCT#: NCT04068896
Study ID: 18-0402
Trial Phase: Phase I
Trial Sponsor: NGM Biopharmaceuticals, Inc
Therapies Used in This Trial: Nab-paclitaxel, Gemcitabine, NGM120